Lv3
320 积分 2024-06-07 加入
1353P Effect of TP53 co-mutation in non-small cell lung cancer (NSCLC) with driver mutations
4个月前
已完结
515MO Phase Ib study of telisotuzumab vedotin (Teliso-V) and osimertinib in patients (Pts) with advanced EGFR-mutated (Mut), c-Met overexpressing (OE) non-small cell lung cancer (NSCLC): Final efficacy and safety updates
5个月前
已完结
[Correlation between common driver gene variations and clinicopathological typing in lung adenocarcinoma]
7个月前
已完结
Frequency of MET amplification determined by comprehensive next-generation sequencing (NGS) in multiple solid tumors and implications for use of MET inhibitors
8个月前
已关闭
7 Concordance of MET amplification detection between FISH and NGS in NSCLC
8个月前
已完结
皖公网安备34019202002308
